Insulin Product description The Competitive Intelligence Report Insulin as of October 2008 provides a competitor analysis in the development pipeline of novel insulin-based products for treatment of type 1 and 2 diabetes. The report also includes the diabetes R&D portfolios of those companies with emerging diabetes drugs (incl. R&D projects for established targets). Insulin therapy has evolved in the last century from purified bovine or porcine insulin to biosynthetic human insulin to recombinant human insulin and eventually to recombinant insulin analogs as the 3rd generation of human insulin. The worldwide market of the major human insulin products in 2007 was US$ 10.2 bln. Insulin analogs posted double digit sales growth due to successive replacement (67.5 % of total sales) of 2nd generation human insulin. Three companies dominate the worldwide insulin market, but experience more and more competition in volume sales of insulin by local manufacturers in off-patent countries, especially in China, India and Russia. The first Indian company is conducting clinical trials in the US with its rhu insulin and even plans to develop and launch a biosimilar insulin analog in the Western countries upon patent expiry in 2014. Three companies in off-patent countries have locally produced insulin analogs either in the market or in pre-registration phases. The next generations of insulin will be “tailored” insulin and oral insulin. Tailored insulin analogs and other long-acting insulins for injection with drug delivery solutions aim at optimized pharmacokinetic profiles in order to avoid hyper- and hypo-glycemic episodes. After the failure of inhaled insulin (only one clinical stage project left), most of the R&D efforts are now made on oral insulin products. The pipeline of oral insulin shows at least seven different oral insulin formulations in clinical development, and at least six in preclinical development. The first oral insulin product is already marketed and in advanced registration in many countries. Further six different projects with non-injectable drug delivery of insulin are in clinical development: intranasal, transdermal and rectal application. The Competitor Analysis Insulin also provides the insulin product portfolios and R&D pipelines of major players from Big Pharma, leading insulin players in off-patent countries and specialty biotech companies. The report includes a compilation of current active projects in research and development of novel insulin-based products. Competitor projects are listed in a tabular format providing information on: - Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Index - Insulin Market: Sales of Major Products in 2007
- Rec Human Insulin for Injection (2nd Generation)
- Biosimilar Rec Human Insulin for Injection (2nd Generation)
- Rhu Insulin (2nd Generation) in Off-Patent Countries: China
- Rhu Insulin (2nd Generation) in Off-Patent Countries: Russia
- Rhu Insulin (2nd Generation) in Off-Patent Countries: India
- Rhu Insulin (2nd Generation) in Off-Patent Countries: Others
- Modern Insulin Analogs (3rd Generation) for Injection
- Biosimilar Modern Insulin Analogs (3rd Generation)
- Tailored Insulin Analogs (4th Generation) for Injection
- Human Insulin with Drug Delivery for Injection
- Other Long-Acting Insulin for Injection
- Transgenic Human Insulin for Injection
- Inhaled Insulin
- Oral Insulin
- Transdermal Insulin
- Rectal Insulin
- Intranasal Insulin
Corporate Insulin Product Portfolio and R&D Pipelines: - Access Pharmaceuticals
- Altea Therapeutics
- Apollo Life Science
- Aradigm
- Ascendis Pharma (ex Complex Biosystems)
- Bio Sidus
- Biodel
- BioSante Pharmaceuticals
- Biotek & Tonghua Dongbao Pharmaceutical Co.
- Biocon
- Bioton
- CPEX Pharmaceuticals (ex Bentley Pharmaceuticals)CoGenesys (Teva Pharmaceutical Industries)
- ConjuChem
- CoreMed
- Diamed Pharmaceuticals
- Eli Lilly
- Emisphere Technologies
- Flamel Technologies
- Gan & Lee Pharmaceutical Co.
- Generex Biotechnology
- Halozyme Therapeutics
- Laboratorios Cryopharma
- Lipoxen
- MannKindMDRNA (ex Nastech Pharmaceutical Co.)
- Metabolex Pharmaceuticals
- Nektar Therapeutics
- Novo Nordisk
- Oramed Pharmaceuticals
- Pharmstandard (Russia)
- Phosphagenics
- PR Pharmaceuticals
- Proxima Concepts (Diabetology Ltd)
- Qdose = JV of MicroDose Technologies & Vectura (ex Innovata)
- Sanofi-Aventis
- Schering-Plough (Diosynth Biotechnology)
- SciGenSemBioSys
- Shanghai Dongbao Biopharmaceutical Co.
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry
- Shenzhen Kexing Biotech
- Shreya Life Sciences
- Therapeutic Proteins Limited (TPL)
- Tonghua Dongbao Pharmaceutical Co.
- Transgene Biotek
- TransPharma Medical
- USV (India)
- Wockhard.
- Wanbang Biopharma (Wanbang Biochemical Pharmaceutical Co.)
|
